Posters

Comparison of the clinical outcomes of two diffractive trifocal intraocular lenses

Poster Details

First Author: T.Ferreira PORTUGAL

Co Author(s):    L. Zabala   J. Pinheiro   F. Ribeiro              

Abstract Details

Purpose:

To compare the visual outcomes of patients who underwent cataract surgery with the implantation of one of two diffractive trifocal IOLs (Finevision PODF, PhysIOL or the new Rayone trifocal, Rayner).

Setting:

Two clinical centers, Lisbon, Portugal

Methods:

This prospective comparative case series included patients with cataract that were submitted to phacoemulsification with the implantation of a Finevision PODF IOL (Finevision group) or a Rayone trifocal IOL (Rayone trifocal group). 30 eyes of 15 patients were included in each group. Over a 3-month follow-up period, the main outcome measures were uncorrected distance (UDVA), intermediate at 80 cm (UIVA) and near at 40 cm (UNVA) visual acuities, spherical equivalent (SE) refraction, defocus curves, contrast sensitivity, the reported presence of photic phenomena and the use of spectacles.

Results:

Mean UDVA was 0.03 ±0.09 logMAR (Finevision) and 0.02 ±0.05 (Rayone trifocal) (p=.312), mean UIVA was 0.08 ±0.12 (Finevision) and 0.06 ±0.10 (Rayone trifocal) (p=.453) and mean UNVA was 0.04 ±0.09 (Finevision) and 0.00 ±0.05 (Rayone trifocal) (p=.112). Mean SE was -0.08 ±0.24 (Finevision) and -0.01 ±0.23 (Rayone trifocal). Both IOLs maintained a binocular visual acuity of 0.1 logMAR or better between -3.00 and +0.50 D of defocus. 3 patients (20%) in the Finevision group and 1 patient (6.7%) in the Rayone trifocal group reported moderate haloes or glare. All patients were spectacle independent.

Conclusions:

The implantation of both trifocal IOLs in patients with cataract provided excellent distance, intermediate and near visual outcomes. The predictability of the refractive results and the optical performance were excellent in both groups, with the new Rayone trifocal IOL showing less photic phenomena. Both IOLs allowed all patients in our series to achieve complete spectacle independence.

Financial Disclosure:

None